SLNO vs. CBZ

In the year-to-date period, SLNO achieves a 12.25% return, which is significantly lower than CBZ's 29.81% return. Over the past 10 years, SLNO has underperformed CBZ with an annualized return of -9.77%, while CBZ has yielded a comparatively higher 25.26% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Soleno Therapeutics, Inc. (SLNO) and CBIZ, Inc. (CBZ). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current SLNO Sharpe Ratio is 0.45, which is lower than the CBZ Sharpe Ratio of 0.95. The chart below compares the historical Sharpe Ratios of SLNO and CBZ, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither SLNO nor CBZ has paid dividends to shareholders.

The maximum SLNO drawdown since its inception was -99.86%, roughly equal to the maximum CBZ drawdown of -96.16%. Use the drawdown chart below to compare losses from any high point for SLNO and CBZ. For additional features, visit the drawdowns tool.

Soleno Therapeutics, Inc. (SLNO) has a higher volatility of 12.79% compared to CBIZ, Inc. (CBZ) at 7.89%. This indicates that SLNO's price experiences larger fluctuations and is considered to be riskier than CBZ based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Soleno Therapeutics, Inc. and CBIZ, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.